One & One Green Technologies stock soars 100% after IPO debut
A ten percent owner, Reprogrammed Interchange LLC, of Vor Biopharma Inc (NASDAQ:VOR), along with Reid Hoffman, reported selling shares of common stock on October 6 and 7, 2025, for a total value of approximately $3.5 million. The biotech company, currently valued at $229 million, has seen its stock surge over 200% in the past six months, according to InvestingPro data.
The sales, executed in multiple transactions, involved a total of 98,487 shares. The prices obtained for these shares ranged from $33.8369 to $37.7743. The stock has recently experienced significant volatility, dropping nearly 14% in the past week, while maintaining a remarkable 148% gain over the last year. InvestingPro subscribers have access to 12 additional key insights about VOR’s financial health and market performance, including detailed analysis of its cash position and profitability metrics.
In other recent news, Vor Bio announced that clinical data from a Phase 3 study of telitacicept in adults with primary Sjögren’s disease will be presented at the upcoming ACR Convergence 2025 conference in Chicago. This follows another announcement that Vor Bio will present 48-week clinical data from a Phase 3 study of telitacicept for generalized myasthenia gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting in San Francisco. Stifel has upgraded Vor Biopharma from Hold to Buy, raising its price target to $55.00, citing increased confidence in the telitacicept drug prospects. Vor Bio also filed a preliminary prospectus for the potential resale of up to 50,999,999 shares of its common stock by selling stockholders. These shares would be issued upon exercise of outstanding warrants, including those to a subsidiary of RemeGen Co. Ltd. Additionally, Vor Bio appointed Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer, bringing over 20 years of experience to the company. These developments highlight Vor Bio’s ongoing efforts in advancing its clinical programs and enhancing its leadership team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.